Black Rock Inc. Contrafect Corp Transaction History

Black Rock Inc.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 13, 2023	BUY	$0.09 - $0.19 $144 - $305	1,606 Added 0.31%	519,432 $51,000
Q3 2022 Nov 14, 2022	SELL	$0.18 - $3.51 $547 - $10,684	-3,044 Reduced 0.58%	517,826 $86,000
Q2 2022 Aug 12, 2022	SELL	$2.79 - $4.45 $15,861 - $25,298	-5,685 Reduced 1.08%	520,870 $1.6 Million
Q1 2022 May 12, 2022	SELL	$2.26 - $3.84 $8,224 - $13,973	-3,639 Reduced 0.69%	526,555 $1.92 Million
Q4 2021 Feb 10, 2022	BUY	$2.47 - $4.14 $10,603 - $17,773	4,293 Added 0.82%	530,194 $1.4 Million
Q3 2021 Nov 09, 2021	SELL	$3.19 - $4.43 $23,229 - $32,259	-7,282 Reduced 1.37%	525,901 $2.13 Million
Q2 2021 Aug 11, 2021	BUY	$3.58 - $4.9 $1.91 Million - $2.61 Million	533,183 New	533,183 $2.35 Million

49.2K

Ticker CFRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,332,700
Market Cap $1.18M
Description
ContraFect Corporation, a clinical-stage biotechnology company, discovers and develops therapeutic protein and antibody products for the treatment of life-threatening and drug-resistant infectious diseases in the United States. Its lead program includes Exebacase, a lysin, which is in Phase III clinical trials for the treatment of staphylococcus...

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

Stay updated on Black Rock Inc. with notifications on news.